Skip to main content
Equibles
NTHI $2.77 +1.84%
NTHI logo
NTHI · Neonc Technologies Holdings, Inc.
Track NTHI — free

Use NTHI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NTHI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.77 +0.05 (+1.84%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 10, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors raise substantial doubt regarding the Company's ability to continue as a going concern one year from the issuance date of this Form 10-Q. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company is actively taking steps to mitigate the substantial doubt about the Company's ability to continue as a going concern, including pursuing additional financing.”
View the 10-Q filed Aug 10, 2026
Market Cap
$70.55M
Shares
25.94M
Volume · Oct 20 102.23K Avg daily vol (3M) 196.11K
All webcasts

Earnings call · FY2026 Q2

Neonc Technologies Holdings, Inc. (NTHI) Q2 2026 Earnings Call

Concluded Aug 12, 2026
Aug 12, 2026 0 turns
Period
FY2026 Q2
Runtime
—
Sources
2 artifacts
Revenue $0
Diluted EPS -$0.58
Net income -$14.24M
Open full screen 8-K 10-Q

Executive readout · one minute

Webcast research workspace

Read the call alongside every captured source. 8-K earnings release, 10-Q stay in one workspace.

FDA regulatory path 31 Phase 2 efficacy results 27 Intranasal brain delivery platform 21 Historical data uncertainty 9 IDH1 mutant indication 9 Mechanism of action 7

Management tone

Confident

Net tone +62 · low hedging

Grounding quotes
  • “NEO 100-1 Phase 2 met its primary endpoint. Survival is the standout result. Medium overall survival was 26.1 month, measured from the start of NIA 100 at recurrence, a setting which current salvage therapy delivers roughly only six to nine months.”
  • “We have already finished phase one, and those results have already been discussed with the FDA in terms of future trial.”
  • “what we believe that our type B meeting with the FDA will be is to align on a single accelerated approval design. It'll be a randomized approved design. Our primary endpoint will be median overall survival. We will have a pre-specified interim analysis to support the accelerated approval.”
  • “Especially for the pediatric population, we've used the largest amount of compassionate uses in the pediatric platform. If you go on our website, You can see some of the progress these kids are making and the drugs doing guys' work.”

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

8-K earnings release Filed Aug 10, 2026 10-Q report Filed Aug 10, 2026 Company webcastOpen the original investor-relations page
Full-screen source Call document

NTHI alerts

Neonc Technologies Holdings, Inc.

Create a free account or sign in to receive transcript alerts at your email address.

Continue to sign in
Read transcripts like this one from Claude, ChatGPT or your own code with the earnings call transcript API →